PubMed Health⌕ Search

PubMed · 16749290

[Multivessel percutaneous coronary interventions. When incomplete revascularization may represent a therapeutic option].

Abstract

Scientific evidence that prognosis of patients with ischemic heart disease, treated by either surgery or percutaneous revascularization, is similar, has led interventional cardiologists to search for an aggressive approach in percutaneous revascularization of patients with multivessel disease. It is still matter of debate which strategy is preferable between pursuing complete revascularization or performing revascularization of the culprit vessel and later of the other vessels. According to American and European guidelines for percutaneous coronary intervention (PCI) in patients with acute coronary syndromes with ST-segment elevation and multivessel disease, primary angioplasty should only be directed to the infarct-related artery (culprit vessel), with decision about PCI of non-culprit lesions guided by objective evidence of residual ischemia at later follow-up. PCI should not be performed in a non-infarct-related artery at the time of primary angioplasty in patients without hemodynamic impairment. In patients with acute coronary syndromes without persistent ST-segment elevation the decision to perform either culprit vessel or complete revascularization can be made on individual basis; in patients with favorable anatomy, the competent practitioner can perform either single or multivessel PCI with a high likelihood of success and low risk of morbidity and mortality. The endothelial dysfunction induced by coronary angioplasty, the occurrence of post-procedural infarction and contrast-induced nephropathy, the X-ray exposure, the problem of the informed consent, the procedural costs are aspects that strongly support a strategy based on staged revascularization when appropriate.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Fabrizio Ugo, Emilia Solinas, Diego Ardissino. 2006. [Multivessel percutaneous coronary interventions. When incomplete revascularization may represent a therapeutic option].. https://pubmed.ncbi.nlm.nih.gov/16749290/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A quality guarantee in acute coronary syndromes: the American College of Cardiology's Guidelines Applied in Practice program taken real-time.

BACKGROUND: Wide variation exists in the management of acute coronary syndromes (ACSs), which includes an apparent underutilization of evidence-based therapies. We have previously demonstrated that application of the American College of Cardiology Guidelines Applied in Practice (GAP) tools can improve quality indicator rates and outcomes of patients hospitalized with ACS. OBJECTIVE: To determine whether a real-time system for monitoring key quality-of-care indicators using GAP would improve both process indicators and outcomes beyond those of the initial implementation of GAP. DESIGN: Prospective patient identification, prospective chart coding, retrospective data abstraction. PATIENTS: All patients with ACS admitted (N = 3189) to our institution between January 1, 1999, and December 2004; 2019 studied before real-time implementation from January 1, 1999, to June 30, 2002, and 1170 studied during real-time implementation from July 1, 2002, to December 31, 2004. MAIN OUTCOME MEASURE: The effect of real-time monitoring of key quality indicators on inhospital therapy and outcomes, and 6-month outcomes in patients admitted with ACS. RESULTS: The real-time GAP implementation correlated with more frequent use of inhospital angiotensin-converting enzyme inhibitors (72.7% vs 63.7%, P < .0001), beta blockers (93.0% vs 89.7%, P = .0016), statins (81.2% vs 65.9%, P < .0001), antiplatelet agents (69.2% vs 22.5%, P < .0001), and glycoprotein IIb/IIIa inhibitors (35.5% vs 26.7%, P < .0001). There were fewer episodes of inhospital congestive heart failure (3.85% vs 8.77%, P < .0001) and major bleeding events (3.2% vs 7.9%, P < .0001) after the real-time system was adopted. Real-time GAP also resulted in higher discharge rates of aspirin (92.1% vs 86.5%, P < .0001), beta blockers (86.8% vs 79.1%, P < .0001), statins (81.2% vs 64.7%, P < .0001), and angiotensin-converting enzyme inhibitors (67.1% vs 55.5%, P < .0001). Real-time GAP implementation was associated with fewer rehospitalizations for heart disease (19.8% vs 25.2%, P = .0014), myocardial infarction (3.5% vs 5.4%, P = .0243), and combined death/cerebrovascular accident/myocardial infarction (9.5% vs 13.9%, P = .0009) during the first 6 months after discharge. CONCLUSION: The institution of a formal system to review and "guarantee" key quality-of-care indicators real time in the hospital is associated with improved outcomes in patients admitted with ACS. The combination of American College of Cardiology's GAP program and its real-time implementation leads to higher use of evidence-based therapies and correspondingly better outcomes than those associated with the initial GAP implementation.

Angina, Unstable↗